| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BX-795 | GDSC1000 | pan-cancer | AAC | 0.096 | 0.007 |
| mRNA | MG-132 | CTRPv2 | pan-cancer | AAC | 0.18 | 0.007 |
| mRNA | bid1870 | gCSI | pan-cancer | AAC | -0.15 | 0.007 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.008 |
| mRNA | GSK690693 | GDSC1000 | pan-cancer | AAC | 0.088 | 0.008 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.1 | 0.008 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.09 | 0.008 |
| mRNA | cyanoquinoline 11 | CTRPv2 | pan-cancer | AAC | 0.15 | 0.008 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.093 | 0.008 |
| mRNA | KPT185 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.008 |